GenSight Biologics S.A. GSGTF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -466.13% | -514.50% | -41.80% | -43.35% | -121.25% |
| Total Other Revenue | 36.45% | 47.93% | -13.37% | -15.60% | -56.26% |
| Total Revenue | -1,964.42% | -2,127.53% | -26.46% | -28.39% | -97.13% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -1,964.42% | -2,127.53% | -26.46% | -28.39% | -97.13% |
| SG&A Expenses | 20.63% | 30.86% | -8.22% | -10.62% | -5.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.06% | 24.82% | -42.89% | -44.38% | -21.04% |
| Operating Income | -28.77% | -39.70% | 44.64% | 46.09% | 3.27% |
| Income Before Tax | -50.87% | -63.68% | 32.02% | 33.80% | -25.89% |
| Income Tax Expenses | 111.76% | 112.77% | -72.94% | -73.86% | -288.89% |
| Earnings from Continuing Operations | -51.08% | -63.91% | 32.10% | 33.88% | -25.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.08% | -63.91% | 32.10% | 33.88% | -25.62% |
| EBIT | -28.77% | -39.70% | 44.64% | 46.09% | 3.27% |
| EBITDA | -31.44% | -42.59% | 42.32% | 43.83% | -2.18% |
| EPS Basic | 4.96% | 5.94% | 56.25% | 57.28% | 25.79% |
| Normalized Basic EPS | 5.65% | 6.15% | 56.22% | 57.20% | 25.32% |
| EPS Diluted | 4.96% | 5.94% | 56.25% | 57.28% | 25.79% |
| Normalized Diluted EPS | 5.65% | 6.15% | 56.22% | 57.20% | 25.32% |
| Average Basic Shares Outstanding | 59.34% | 73.91% | 54.84% | 54.84% | 69.19% |
| Average Diluted Shares Outstanding | 59.34% | 73.91% | 54.84% | 54.84% | 69.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |